UBCS385

UBCS385
Clinical data
Drug class	Sirtuin-4 (SIRT4) inhibitor
Identifiers
	IUPAC name N-[5-(4-nitrophenyl-1-sulfonyl)-1,3-thiazol-2-yl]-2-[(5-chloro-1H-1,3-benzimidazol-2-yl)sulfanyl]-2-phenylacetamide;
Chemical and physical data
Formula	C24H16ClN5O5S3
Molar mass	586.05 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(Cl)cc2c1NC(=N2)SC(c1ccccc1)C(=O)NC1=NC=C(S1)S(=O)(=O)c1ccc([N+](=O)[O+])cc1;
	InChI InChI=InChI=1S/C24H18ClN5O5S3/c25-15-6-11-18-19(12-15)28-24(27-18)37-21(14-4-2-1-3-5-14)22(31)29-23-26-13-20(36-23)38(34,35)17-9-7-16(8-10-17)30(32)33/h1-13,21H,32H2,(H,27,28)(H,26,29,31)/q+2; Key:BZKNNWDMWJKHJB-UHFFFAOYSA-N;

UBCS385 is a drug which acts as a sirtuin-4 (SIRT4) inhibitor. It also inhibits SIRT2 with around the same affinity, but has reasonable selectivity over SIRT1, SIRT3, SIRT5 and SIRT6. As one of the first ligands developed that inhibits SIRT4 with high potency, UBCS385 is useful for basic research into the structure and function of the sirtuin-4 enzyme complex.^[1]^[2]

References

^ Pannek M, Alhalabi Z, Tomaselli D, Menna M, Fiorentino F, Robaa D, et al. (February 2024). "Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity". Journal of Medicinal Chemistry. 67 (3): 1843–1860. doi:10.1021/acs.jmedchem.3c01496. PMID 38253001.
^ Bursch KL, Goetz CJ, Smith BC (March 2024). "Current Trends in Sirtuin Activator and Inhibitor Development". Molecules. 29 (5): 1185. doi:10.3390/molecules29051185. PMC 10934002. PMID 38474697.

[1] Pannek M, Alhalabi Z, Tomaselli D, Menna M, Fiorentino F, Robaa D, et al. (February 2024). "Specific Inhibitors of Mitochondrial Deacylase Sirtuin 4 Endowed with Cellular Activity". Journal of Medicinal Chemistry. 67 (3): 1843–1860. doi:10.1021/acs.jmedchem.3c01496. PMID 38253001.

[2] Bursch KL, Goetz CJ, Smith BC (March 2024). "Current Trends in Sirtuin Activator and Inhibitor Development". Molecules. 29 (5): 1185. doi:10.3390/molecules29051185. PMC 10934002. PMID 38474697.

[1]

[2]